[go: up one dir, main page]

MA35750B1 - Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c) - Google Patents

Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)

Info

Publication number
MA35750B1
MA35750B1 MA37158A MA37158A MA35750B1 MA 35750 B1 MA35750 B1 MA 35750B1 MA 37158 A MA37158 A MA 37158A MA 37158 A MA37158 A MA 37158A MA 35750 B1 MA35750 B1 MA 35750B1
Authority
MA
Morocco
Prior art keywords
vhc
difluoro
hepatitis
virus
inhibitors
Prior art date
Application number
MA37158A
Other languages
English (en)
Inventor
Jing Zhang
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA35750B1 publication Critical patent/MA35750B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des composés représentés par la formule i : elle concerne également des compositions pharmaceutiques comprenant les composés de formule i, des méthodes d'utilisation de ces composés de formule i et/ou les compositions contenant les composés de formule i pour le traitement du vhc.
MA37158A 2011-12-20 2014-06-25 Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c) MA35750B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577707P 2011-12-20 2011-12-20
PCT/EP2012/075779 WO2013092481A1 (fr) 2011-12-20 2012-12-17 Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)

Publications (1)

Publication Number Publication Date
MA35750B1 true MA35750B1 (fr) 2014-12-01

Family

ID=47504913

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37158A MA35750B1 (fr) 2011-12-20 2014-06-25 Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)

Country Status (31)

Country Link
US (1) US9108999B2 (fr)
EP (1) EP2794629B1 (fr)
JP (1) JP5982007B2 (fr)
KR (1) KR101765997B1 (fr)
CN (1) CN104011061B (fr)
AU (1) AU2012357940B2 (fr)
BR (1) BR112014013661B1 (fr)
CA (1) CA2856179C (fr)
CL (1) CL2014001562A1 (fr)
CO (1) CO6960551A2 (fr)
CR (1) CR20140238A (fr)
CY (1) CY1119056T1 (fr)
DK (1) DK2794629T3 (fr)
EA (1) EA024297B1 (fr)
ES (1) ES2636448T3 (fr)
HU (1) HUE033727T2 (fr)
IL (1) IL232505B (fr)
LT (1) LT2794629T (fr)
MA (1) MA35750B1 (fr)
MX (1) MX350809B (fr)
MY (1) MY171577A (fr)
PE (1) PE20141423A1 (fr)
PH (1) PH12014501134A1 (fr)
PL (1) PL2794629T3 (fr)
PT (1) PT2794629T (fr)
RS (1) RS56212B1 (fr)
SG (1) SG11201403364PA (fr)
SI (1) SI2794629T1 (fr)
UA (1) UA111761C2 (fr)
WO (1) WO2013092481A1 (fr)
ZA (1) ZA201404273B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
BR112014029115A8 (pt) 2012-05-22 2018-04-03 Idenix Pharmaceuticals Inc Composto, composição farmacêutica, e, uso de um composto ou composição
EP2852605B1 (fr) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
EP2852604B1 (fr) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
ES2597757T3 (es) 2012-05-25 2017-01-20 Janssen Sciences Ireland Uc Nucleósidos de uracilespirooxetano
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
BR112015007698A2 (pt) 2012-10-08 2017-08-22 Idenix Pharmaceuticals Inc Centre National De La Recherche Scientifique E Univ Montpellier 2 Science Composto, composição farmacêutica, e, uso de um composto
WO2014099941A1 (fr) * 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
PE20151433A1 (es) * 2012-12-21 2015-10-16 Alios Biopharma Inc Nucleosidos sustituidos, nucleotidos y analogos de los mismos
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014137930A1 (fr) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Nucléosides de thiophosphate pour le traitement du vhc
WO2014137926A1 (fr) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
CA2899763C (fr) * 2013-03-08 2020-03-10 Nanjing Sanhome Pharmaceutical Co., Ltd. Compose de nucleoside phosphoramidate et son utilisation
EP2970357B1 (fr) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Pronucléotides de phosphoramidate d'acide aminé de 2'-cyano, azido et amino nucléosides pour le traitement du virus de l'hépatite c (vhc)
EP2981542B1 (fr) * 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoronucléosides pour le traitement du vhc
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
CA2912682C (fr) 2013-05-16 2021-07-06 Riboscience Llc Derives de nucleosides 4'-fluoro-2'-methyle substitues
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
EP3027636B1 (fr) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC Phosphoramidate de d-acides aminés pronucleotidiques dérivés de pyrimidine halogenée pour des maladies du foie
WO2015054465A1 (fr) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Nucléosides substitués, nucléotides substitués et analogues de ceux-ci
WO2015061683A1 (fr) * 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
WO2015161137A1 (fr) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
EP3160475B1 (fr) 2014-06-24 2024-01-03 Janssen Pharmaceuticals, Inc. Nucléosides et nucléotides substitués pour traiter les infections dues aux filoviridae
WO2015200219A1 (fr) 2014-06-24 2015-12-30 Alios Biopharma, Inc. Nucléosides substitués, nucléotides et analogues de ceux-ci
CN105294795B (zh) * 2014-11-20 2019-01-15 南京曼杰生物科技有限公司 核苷氨基磷酸酯衍生物及其应用
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CA2997170A1 (fr) * 2015-09-02 2017-03-09 Abbvie Inc. Derives anti-viraux de tetrahydrofurane
EP3454862B1 (fr) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
AU2018335411B2 (en) 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
IL277160B2 (en) * 2018-03-07 2024-10-01 Univ Emory 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU498131B2 (en) 1974-02-26 1979-02-15 Ciba-Geigy Ag Production of cephems by cyclization
US4147864A (en) 1975-02-20 1979-04-03 Ciba-Geigy Corporation Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds
US4322347A (en) 1978-04-03 1982-03-30 Bristol-Myers Company 2-Carbamoyloxymethyl-penicillin derivatives
WO1986006380A1 (fr) 1985-04-30 1986-11-06 Takeda Chemical Industries, Ltd. Composes antibacteriens, utilisation et preparation
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
WO1997040028A1 (fr) 1996-04-23 1997-10-30 Vertex Pharmaceuticals Incorporated Derives d'uree agissant comme inhibiteurs de l'enzyme impdh
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
CA2282398A1 (fr) 1997-03-14 1998-09-17 Steven M. Ronkin Inhibiteurs de l'enzyme impdh
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
NZ503263A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
WO2000006529A1 (fr) 1998-07-27 2000-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Derives de dicetoacides utilises comme inhibiteurs de polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
ID27787A (id) 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
EP1109580A4 (fr) 1998-09-04 2004-05-26 Viropharma Inc Methodes de traitement ou de prevention des infections virales et des maladies associees
CA2345347A1 (fr) 1998-09-25 2000-04-06 Viropharma Incorporated Procedes de traitement ou de prevention d'infections virales et de maladies associees
WO2000056331A1 (fr) 1999-03-19 2000-09-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de l'enzyme impdh
EP1225899A2 (fr) 1999-11-04 2002-07-31 Virochem Pharma Inc. Procede de traitement ou de prevention de l'infection virale par flaviviridae faisant appel a des analogues des nucleosides
JP2004509066A (ja) 2000-05-10 2004-03-25 スミスクライン・ビーチャム・コーポレイション 新規抗感染症薬
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
BR0210357A (pt) 2001-06-11 2004-06-29 Shire Biochem Inc Composto e métodos para o tratamento ou a prevenção de infecções pelo flavivìrus
WO2002100846A1 (fr) 2001-06-11 2002-12-19 Shire Biochem Inc. Composes et methodes de traitement ou de prevention d'infections a flavivirus
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (fr) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
EP2335700A1 (fr) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
EP1440068A1 (fr) 2001-11-02 2004-07-28 Glaxo Group Limited Derives d'acyl-dihydro-pyrrole utilises comme inhibiteurs du vhc
ATE370137T1 (de) 2001-11-02 2007-09-15 Glaxo Group Ltd 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
WO2003037894A1 (fr) 2001-11-02 2003-05-08 Glaxo Group Limited Derives de heteroaryle acyle pyrrolidine a 4-(5-elements) utiles comme inhibiteurs de vhc
AU2003269890A1 (en) 2002-06-21 2004-01-06 Isis Pharmaceuticals, Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003263978A1 (en) * 2002-08-01 2004-02-23 Board Of Trustees Of The Leland Stanford Junior University 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
US20050020884A1 (en) 2003-02-25 2005-01-27 Hart Charles C. Surgical access system
WO2004096235A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues de phosphonate anticancereux
WO2005020884A2 (fr) 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides pour traitement des infections a coronavirus, a togavirus et a picornavirus
US7507859B2 (en) 2003-06-16 2009-03-24 Fifth Base Llc Functional synthetic molecules and macromolecules for gene delivery
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP1713822B1 (fr) 2004-01-30 2010-03-17 Medivir AB Inhibiteurs de la serine protease ns-3 du vhc
CA2590115A1 (fr) 2004-12-10 2006-06-15 Emory University Analogues de nucleosides de cyclobutyle a substitution 2' et 3' pour le traitement des infections virales et de la proliferation cellulaire anormale
CN101287472B (zh) * 2005-08-15 2011-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
CA2637879A1 (fr) 2006-02-14 2007-08-23 Merck & Co., Inc. Phosphoramidates d'aryle nucleosidiques pour le traitement d'infections ribovirales dependantes de l'arn
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB2442001A (en) 2006-08-11 2008-03-26 Chembiotech Nanoparticle - i-motif nucleic acid bioconjugates
DE602007008616D1 (de) * 2006-12-11 2010-09-30 Hoffmann La Roche Verfahren zur herstellung von 4'-azidocytidinderivaten
EP2124555B1 (fr) 2007-01-05 2015-07-08 Merck Sharp & Dohme Corp. Phosphoramidates d'aryle nucléosidiques destinés au traitement de l'infection virale d'arn arn dépendante
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2011133871A2 (fr) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Dérivés d'extrémité 5'
EP2805960A1 (fr) 2010-07-19 2014-11-26 Gilead Sciences, Inc. Procédés pour la préparation de promédicaments de phosphoramidate pur diastéromérique
US9334300B2 (en) 2011-08-01 2016-05-10 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates

Also Published As

Publication number Publication date
CL2014001562A1 (es) 2014-11-14
PT2794629T (pt) 2017-07-20
CN104011061A (zh) 2014-08-27
ES2636448T3 (es) 2017-10-05
PE20141423A1 (es) 2014-10-16
RS56212B1 (sr) 2017-11-30
KR101765997B1 (ko) 2017-08-07
IL232505A0 (en) 2014-06-30
MX2014007023A (es) 2014-09-12
CA2856179C (fr) 2017-02-28
SG11201403364PA (en) 2014-07-30
US9108999B2 (en) 2015-08-18
CA2856179A1 (fr) 2013-06-27
MY171577A (en) 2019-10-21
PH12014501134B1 (en) 2014-07-28
SI2794629T1 (sl) 2017-10-30
AU2012357940A1 (en) 2014-05-29
UA111761C2 (uk) 2016-06-10
PH12014501134A1 (en) 2014-07-28
DK2794629T3 (en) 2017-07-24
JP2015500852A (ja) 2015-01-08
NZ625342A (en) 2016-07-29
EA024297B1 (ru) 2016-09-30
KR20140108290A (ko) 2014-09-05
HK1199036A1 (en) 2015-06-19
CR20140238A (es) 2014-06-20
EP2794629A1 (fr) 2014-10-29
HK1200836A1 (en) 2015-08-14
MX350809B (es) 2017-09-20
EA201491179A1 (ru) 2014-11-28
BR112014013661A8 (pt) 2017-12-19
BR112014013661B1 (pt) 2020-10-27
AU2012357940B2 (en) 2017-02-16
PL2794629T3 (pl) 2018-02-28
IL232505B (en) 2019-02-28
CY1119056T1 (el) 2018-01-10
US20150004135A1 (en) 2015-01-01
EP2794629B1 (fr) 2017-05-24
ZA201404273B (en) 2015-09-30
HUE033727T2 (en) 2018-01-29
WO2013092481A1 (fr) 2013-06-27
BR112014013661A2 (pt) 2017-06-13
CN104011061B (zh) 2017-06-13
LT2794629T (lt) 2017-07-25
JP5982007B2 (ja) 2016-08-31
CO6960551A2 (es) 2014-05-30

Similar Documents

Publication Publication Date Title
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA34400B1 (fr) Dérivés d'acide 2-quinolinyl-acétique en tant que composés antiviraux contre le vih
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA34397B1 (fr) Dérivés d'acide napht-2-ylacétique dans le traitement du sida
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA39317A1 (fr) Dérivés de nucléosides à substitution 4'-difluorométhyle utilisés en tant qu'inhibiteurs de la réplication de l'arn du virus de la grippe
MA38675A1 (fr) Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués utiles pour inhiber la replication de l'hepatite c (hcv)
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA39783B1 (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA200870423A1 (ru) Производные триазолпиразинов, применимые в качестве противораковых агентов
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA29240B1 (fr) Derives d'indole pour le traitement d'infections virales
EA201071329A1 (ru) Диамидные производные адамантана и их применение
EA201100299A1 (ru) Органические соединения
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201100503A1 (ru) Глюкозидные производные и их применения
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ